Psychedelic Therapy for Lasting Transformation with Dr Michael Yang

The medicine may open the door, but the daily practice does the rewiring

Dr Michael Yang makes a deliberately provocative claim in this conversation: that we may have solved a portion of mental healthcare for some people by combining psychedelic or ketamine-assisted state shifts with disciplined, everyday follow-through. The useful part of that claim is not triumphalism. It is the recognition that some people do seem to change more quickly when entrenched patterns are loosened, the nervous system becomes a little less rigid, and the person then does real work with what opens up.

What this episode gets right is the pairing of possibility with humility. Michael is enthusiastic about ketamine, altered states, and awe. He is also talking as a clinician who cares about safety, commitment, and the difference between a moving experience and a durable life change.

Use this guide if you are trying to think more clearly about:

• what ketamine or psychedelic-assisted therapy can realistically help with;
• why some people experience rapid relief without durable transformation;
• why screening, support, and integration are not optional extras;
• how awe and perspective shifts can help without becoming spiritual entertainment;
• what it looks like to turn a profound session into nervous-system practice.

✻1This guide is educational only and is not medical advice, psychiatric advice, or an endorsement of unsupervised psychedelic or ketamine use. Ketamine can help in some contexts, especially treatment-resistant depression and acute suicidality, but benefits may be transient and it is not appropriate for everyone. Careful screening for psychiatric and medical risk, qualified support, and follow-up matter.

Read the bold claim carefully: a springboard is not a cure

Michael's strongest idea is that altered states can act like a springboard. In his framing, many people are stuck because old memory structures, habits, and emotional defenses are hard to dislodge through insight alone. His phrase for this is memorable: psychedelics can make the brain more "squishy."

That framing is directionally useful, but it needs translation:

What the conversation points toward	More grounded version
"We've solved mental healthcare"	Some people appear to benefit when symptom relief, perspective shift, and behavioral follow-through line up.
Ketamine creates a springboard	Ketamine can rapidly reduce depressive symptoms or suicidal thinking for some patients, often for a limited time window rather than as a permanent fix.12
Psychedelics dislodge stuck patterns	Altered states may interrupt rigid narratives or defensive loops, but the result still depends on preparation, setting, and what happens next.34
The experience itself transforms you	The experience can reorient you. Repetition, support, and practice are what make the reorientation stick.

This matters because the conversation is rich in philosophical confidence, but the research base is still mixed. Ketamine has some of the better evidence in this general territory, especially for rapid antidepressant and anti-suicidal effects in selected patients, yet those effects are often short-lived and protocols vary widely.² Psychedelic-assisted therapy more broadly remains promising and uneven: some results are striking, but not every diagnosis, every person, or every clinical setting has the same level of evidence.

A clean NSM translation: state change is not the same thing as trait change. The first can happen quickly. The second usually requires repetition and an environment that supports the new pattern.

Screening and support are part of the treatment

One of the easiest mistakes with psychedelic content is to focus on the molecule and ignore the selection process. This episode is not a detailed contraindications interview, but the broader clinical literature is clear that screening is part of the intervention, not just paperwork.⁵⁶⁴

Questions worth asking before any ketamine or psychedelic-assisted treatment:

Screening domain	Why it matters
Personal or family history of psychosis or mania	Some programs exclude or heavily caution these cases because altered states can destabilize vulnerable people.54
Blood pressure, cardiovascular disease, aneurysm risk, recent cardiac events	Ketamine can transiently raise blood pressure and may be inappropriate or require closer monitoring in some medical situations.56
Current suicidality, dissociation, substance-use risk, or severe instability	Higher-acuity support or a different level of care may be needed. Access should not outrun containment.
Medication interactions and overall treatment plan	The question is not only "Can I do this?" but also "Who is coordinating my care before, during, and after?"
Support system and re-entry environment	An altered state is easier to metabolize when the person is not returning immediately to chaos, secrecy, or isolation.

For classic psychedelic research, safety guidelines have long emphasized psychiatric screening, rapport, preparation, safe surroundings, and sustained interpersonal support.⁴ Ketamine is pharmacologically different, but the broader principle still holds: you do not separate the substance from the container.

That is especially important because this conversation can sound inspiring enough to make someone think, "I just need the right experience." Often the better question is: "What would make this under-supported or unsafe for me right now?"

Relief, insight, and transformation are not the same outcome

One of the most grounded moments in the episode comes when Michael describes a patient with longstanding manic-depressive and suicidal suffering who, in his telling, is kept from feeling suicidal by routine ketamine therapy while still remaining sad.

That anecdote captures something crucial:

1. Symptom relief can be profound even when life is not fully transformed.
2. Not feeling suicidal is already a massive clinical outcome.
3. Even meaningful outcomes do not prove universal cure.

This is where a lot of public discourse goes off the rails. People collapse several different goals into one bucket:

• rapid reduction in suicidal thinking;
• relief from treatment-resistant depression;
• trauma processing;
• existential opening;
• behavior change;
• spiritual insight;
• long-term personality change.

Those are not all the same intervention target.

Michael also draws a distinction between psilocybin and ketamine that is vivid rather than scientific: psilocybin, in his words, can reveal the vastness within the small and natural, while ketamine often moves in the opposite direction, into a deep disconnection or void-like perspective. That metaphor is useful as a subjective report, not as a dosing algorithm. The bigger principle is that different altered states may open different therapeutic doors, and none of them eliminate the need for support and integration.

Awe can reorient you, but it cannot do the reps for you

The most original part of Michael's framing is his emphasis on awe. He compares ketamine-assisted perspective shifts to the astronaut's overview effect: you go up, see the whole thing differently, and come back with a wider map.

That comparison holds up surprisingly well as a therapeutic metaphor.

• Awe can shrink the grip of ordinary rumination.
• Awe can interrupt the sense that your current problem is the whole universe.
• Awe can make meaning feel more available.
• Awe can help people feel less trapped in a single identity or story.

There is emerging literature suggesting that awe can support well-being, meaning, prosociality, and a less self-absorbed perspective, including in domains that overlap with psychedelic experience.⁷ But even there, the honest conclusion is "promising," not "proven cure."

Michael's own metaphor answers the integration problem. A psychedelic session may send you briefly to the space station. That does not make you an astronaut. It gives you a glimpse, then returns you to ordinary gravity. The glimpse matters because it reorients the path. It does not remove the path.

A helpful distinction:

If the session gives you...	The next job is...
relief	protect it with sleep, support, and reduced chaos
insight	translate it into one specific behavioral change
awe	let it widen perspective without turning it into grandiosity
grief or tenderness	give it enough relational support to be metabolized
confusion	slow down and involve qualified help before interpreting everything as revelation

The nervous system usually changes through titrated contact, not one cinematic breakthrough.

Practice

Try Michael Yang's 90% pace practice

This comes from the end of the conversation, where Michael offers a simple but demanding experiment: slow ordinary life down just enough that presence has a chance to appear.

1. Start the morning with one meaningful input. Read one passage, question, or paragraph worth contemplating rather than immediately feeding the mind noise.
2. Carry it through the day. Let that idea occupy attention in the background instead of only rehearsing logistics, fear, or self-criticism.
3. Do ordinary actions at 90% speed. Walk a little slower. Answer a little slower. Transition a little slower. Not dramatically. Just enough to notice the gap.
4. Use the gap. When that extra 10% of rushing falls away, notice breath, muscle tension, impulse, and the space between stimulus and response.
5. Write briefly at night. What changed when you slowed down? Where did you become more present? Where did you speed back up automatically?
6. Choose one repeatable rep. A slower first sip of coffee, a slower walk to the car, one conscious exhale before replying, or five minutes of evening reflection.

The point is not to become tranquil and impressive. The point is to make presence easier to access in ordinary life, because that is where integration either happens or doesn't.

Lasting change needs a daily contemplative rhythm

By the end of the conversation, Michael's answer becomes surprisingly old-fashioned: read something meaningful in the morning, contemplate it through the day, write at night, meditate where you can, and treat every day as a series of chances to transform.

That is important because it keeps psychedelic therapy in proportion. The altered state may loosen the pattern, but the daily contemplative rhythm is what teaches the system a new baseline.

A workable post-session rhythm might look like this:

• protect the first 24-72 hours instead of flooding yourself with stimulation;
• capture images, insights, emotions, and body sensations before they blur into a vague glow;
• discuss the session with a therapist, clinician, or grounded support person if that is part of your care plan;
• translate the experience into one concrete shift: a boundary, apology, rest block, grief ritual, meditation rep, or conversation;
• keep practicing when the glow fades.

Michael repeatedly returns to the same point in different language: if you want to change, you cannot only visit a new state. You have to practice becoming the kind of person who can inhabit it.

That is also where his comments on suffering become useful. He is not offering a slogan that pain is secretly wonderful. He is arguing that suffering is part of what makes us human, expands compassion, and forces the nervous system to confront what matters. In NSM terms, pain is not automatically transformative. But suffering that is met with support, reflection, and practice can become material for deeper regulation and meaning rather than only collapse.

Key takeaways

• Michael Yang's bold thesis is most useful when translated modestly: altered states may create a springboard for change, but they do not replace daily practice.
• Ketamine has real evidence in some contexts, especially rapid antidepressant and anti-suicidal effects, while remaining far from a universal answer.
• Screening for psychosis risk, mania risk, cardiovascular concerns, instability, and support level is part of good care, not bureaucratic friction.
• A moving session can produce relief, insight, awe, or perspective. None of those automatically become lasting transformation.
• Awe may help widen perspective and loosen rumination, but it still has to be integrated into ordinary life.
• The most practical takeaway from the episode is not exotic: slow down slightly, contemplate better questions, and build a daily rhythm that can hold the change.

Free assessment

Take the free nervous system assessment.

If you are exploring therapy, contemplative practice, ketamine-assisted treatment, or other forms of deep inner work, the assessment can help you map your current nervous-system patterns and choose a steadier next step. It is not a medical screening tool or psychedelic suitability test.

Take the assessment →

Continue exploring

• Read Tackling the Mental Health Crisis using Ketamine-Assisted Therapy for a more operational guide to screening, set and setting, and integration.
• Read Somatics, Breathwork & Emotional Fluidity for a body-first approach to meeting difficult material without depending on a pharmacological state shift.
• Read Breathwork for Anxiety for a lower-risk pathway into state change, regulation, and perspective shifts.
• Read The Art and Science of Interoception for a deeper understanding of how internal body awareness shapes regulation, choice, and recovery.

References

1. Berman and colleagues' early randomized, double-blind crossover study in seven patients found rapid antidepressant effects after IV ketamine compared with saline, but the sample was tiny and should be read as early evidence rather than a universal protocol. See Rebecca M. Berman et al., "Antidepressant effects of ketamine in depressed patients," Biological Psychiatry 47, no. 4 (2000): 351-354, https://pubmed.ncbi.nlm.nih.gov/10686270/. ↩
2. A comprehensive systematic review concluded that ketamine shows robust, rapid, and usually transient antidepressant and anti-suicidal effects, while evidence for other indications is less robust and high risk of bias remains a problem. See Zach Walsh et al., "Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review," BJPsych Open (2021), https://pubmed.ncbi.nlm.nih.gov/35048815/. ↩
3. Kew and colleagues reviewed 19 studies combining ketamine and psychotherapy and concluded the approach appears promising, but heterogeneity in diagnoses, routes, therapy types, sequencing, and study design prevents definitive recommendations. See James N. Kew et al., "Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review," BJPsych Open 9, no. 3 (2023), https://pubmed.ncbi.nlm.nih.gov/37128856/. ↩
4. Johnson, Richards, and Griffiths' safety guidelines for human hallucinogen research emphasize psychiatric screening, preparation, a safe environment, rapport, and strong interpersonal support, including exclusion of some people with psychotic vulnerability. Ketamine is not a classic psychedelic, so this is adjacent safety context rather than a ketamine-specific protocol. See Matthew W. Johnson, William A. Richards, and Roland R. Griffiths, "Human hallucinogen research: guidelines for safety," Journal of Psychopharmacology 22, no. 6 (2008): 603-620, https://pubmed.ncbi.nlm.nih.gov/18593734/. ↩
5. An international expert opinion on ketamine and esketamine for treatment-resistant depression identifies primary psychotic disorder, uncontrolled hypertension, central aneurysmal disease, significant valvular disease, recent cardiovascular events, and class III heart failure as exclusions or high-caution situations in many clinical programs. See Roger S. McIntyre et al., "Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation," American Journal of Psychiatry 178, no. 5 (2021), https://pmc.ncbi.nlm.nih.gov/articles/PMC9635017/. ↩
6. A 2024 review describing practical applications to a community ketamine program similarly emphasizes full history and physical examination, blood-pressure considerations, and individualized risk-benefit decisions rather than one-size-fits-all access. See Carson Chrenek et al., "Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada," Frontiers in Psychiatry (2024), https://pmc.ncbi.nlm.nih.gov/articles/PMC10801061/. ↩
7. Monroy and Keltner review evidence that awe can support well-being through shifts in physiology, self-focus, social connection, and meaning, while noting that the field is still building more precise process-level evidence. See Maria Monroy and Dacher Keltner, "Awe as a Pathway to Mental and Physical Health," Perspectives on Psychological Science 18, no. 2 (2023): 309-320, https://pubmed.ncbi.nlm.nih.gov/35994778/. ↩